$15.62
Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story?
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential?
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
Overview
52-week range
$12
$35
15% of range
Avg surprise (last 3)
+6.4%
Avg reaction (last 2)
+1.0%
50% positive
Latest IV / EM
55%
EM ±12.5% · $15 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.39 | $-0.50 | +22.0% | -2.6% | -0.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.39 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.55 | $-0.48 | -14.6% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.38 | $-0.43 | +11.6% | — | +2.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.51 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.11 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.30 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.25 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.42 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.26 | -$0.55 | +52.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | — | $10M | $0 | $0 | — | $439,000 | $9M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-34M | — | $-35M | $-45M | $-35M | — | $-36M | $-14M |
| Net income | $-24M | — | $-24M | $-34M | $-24M | — | $-28M | $-6M |
| EPS (diluted) | $-0.39 | — | $-0.39 | $-0.55 | $-0.38 | — | $-0.51 | $-0.11 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $52M | $52M | $48M | $52M | $74M | $431M | $27M | $15M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $1.00B | $976M | $998M | $1.01B | $1.02B | $1.03B | $666M | $662M |
| Total assets | $1.03B | $1.00B | $1.02B | $1.03B | $1.05B | $1.06B | $695M | $691M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $87M | $45M | $48M | $42M | $38M | $39M | $39M | $34M |
| Total equity | $942M | $957M | $977M | $991M | $1.01B | $1.02B | $656M | $658M |